1LLY:BIT
Eli Lilly And Co
1.017,40 €
arrow_downward
-0,57%(-5,80) 1 ngày
2 thg 10, 17:29:23 GMT+2 · EUR
search
Tất cả mã
| Mã | Giá | Thay đổi | % thay đổi |
|---|
insights_autoĐang tạo thông tin chi tiết hàng đầu cho 1LLY...
Mở
1.023,60 €
Cao
1.031,00 €
Thấp
1.016,00 €
Vốn hoá thị trường
1,10 NT
Khối lượng giao dịch trung bình
382,00
Khối lượng
492,00
Cao nhất trong 52 tuần
1.106,80 €
Thấp nhất trong 52 tuần
640,70 €
Số nhân viên
50 N
Mở
1.023,60 €
Cao
1.031,00 €
Thấp
1.016,00 €
Vốn hoá thị trường
1,10 NT
Khối lượng giao dịch trung bình
382,00
Khối lượng
492,00
Cao nhất trong 52 tuần
1.106,80 €
Thấp nhất trong 52 tuần
640,70 €
Số nhân viên
50 N
Tin bài
Từ các nguồn trên web và đối tác tin tức
AD HOC NEWS
·
1 giờ trước
EUR 1,037.40 at Lang & Schwarz: Eli Lilly stock pre-market minus 0.33 percent versus the prior close
The Motley Fool
·
15 giờ trước
Eli Lilly's Obesity Business Could Become a Much Bigger Healthcare Platform
Benzinga
·
16 giờ trước
Transcript: Eli Lilly Q2 2026 Earnings Conference Call
The Globe and Mail
·
18 giờ trước
How Is Eli Lilly's Oncology Portfolio Poised Ahead of Q3 Earnings?
Hồ sơ
Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.
The company is ranked 4th on the list of largest biomedical companies by revenue and is the most valuable pharmaceutical company worldwide. It is ranked 100th on the Fortune 500 and 138th on the Forbes Global 2000. In November 2025, the company reached a $1 trillion market capitalization, the first health-care company in the world to do so.
The company's primary products are tirzepatide for the treatment of type 2 diabetes, weight loss, and obstructive sleep apnea; abemaciclib for the treatment of advanced or metastatic breast cancers; dulaglutide for the treatment of type 2 diabetes; ixekizumab for the treatment of autoimmune diseases; and empagliflozin for the treatment of type 2 diabetes. Wikipedia
Giới thiệu về Eli Lilly And Co
Giám đốc điều hànhDavid A. Ricks
Số nhân viên50 N
Ngày thành lập1876
Trụ sở chínhIndianapolis, Indiana, Hoa Kỳ
Lĩnh vực-
Trang weblilly.com